Physician profile
Frederick Rogoff
NPI 1649253907
$798.48
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2022: $20.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $144.28 | 2019 | |
| Mallinckrodt Enterprises LLC | $122.01 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $116.12 | 2019 | |
| Akebia Therapeutics INC | $77.23 | 2019 | |
| Vifor Pharma, INC. | $74.03 | 2019 | |
| Lundbeck LLC | $60.29 | 2019 | |
| Amgen INC. | $49.78 | 2019 | |
| Opko Pharmaceuticals, LLC | $47.29 | 2019 | |
| Horizon Therapeutics Plc | $37.93 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $34.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.78 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Rogoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.